Diaceutics Reports Strong FY 2024 Results with Significant Growth and Expansion

The latest announcement is out from Diaceutics ( (GB:DXRX) ).

Diaceutics PLC reported strong financial and commercial performance for FY 2024, with a 39% revenue growth to £32.2 million and a 50% increase in adjusted EBITDA to £4.2 million. The company expanded its sales presence in the US and launched its PMx solution, contributing to its growth momentum. With an order book of £24.9 million and an ARR of £16.8 million, Diaceutics is positioned for continued growth in 2025. The company secured three new enterprise-wide engagements and increased its customer base, working with 18 of the top 20 global pharma companies. Despite macroeconomic uncertainties, Diaceutics remains confident in achieving its growth and profitability targets for 2025.

The most recent analyst rating on (GB:DXRX) stock is a Buy with a £200.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.

More about Diaceutics

Diaceutics is a leading technology and solutions provider to the pharma and biotech industry, offering an end-to-end commercialization solution for precision medicines through data analytics, scientific and advisory services enabled by their platform DXRX – The Diagnostics Network®. The company focuses on ensuring that patients receive the right tests and therapies to positively impact their disease outcomes.

Average Trading Volume: 84,642

Technical Sentiment Signal: Hold

Current Market Cap: £102.7M

Learn more about DXRX stock on TipRanks’ Stock Analysis page.